Low-Dose Aspirin and Pancreatic Cancer Risk—Reply

Risch, Harvey A.

doi:10.1158/1055-9965.epi-17-0208

Cited by 3 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metaregression of this association over time shows a significant decreasing trend in the RR, with an average decrease of 1.9% per year (95% CI, 0.9%-2.8%; P ¼ .00012). 3 Summarizing all 21 studies in this way, a current estimate of the RR of pancreatic cancer for regular use of aspirin is 0.69 (95% CI, 0.62-0.78). 3 All of the cohort studies in the metaregression were conducted such that their case accessions occurred on average during approximately the first one-half of the overall time frame of the accessions (1976-2011), whereas the RRs have been appreciably declining since the midpoint.…”

Section: Dear Editorsmentioning

confidence: 99%

“…3 Summarizing all 21 studies in this way, a current estimate of the RR of pancreatic cancer for regular use of aspirin is 0.69 (95% CI, 0.62-0.78). 3 All of the cohort studies in the metaregression were conducted such that their case accessions occurred on average during approximately the first one-half of the overall time frame of the accessions (1976-2011), whereas the RRs have been appreciably declining since the midpoint. Both the case control and cohort studies included here have strengths and weaknesses, but both types convey relevant data on the association.…”

Section: Dear Editorsmentioning

confidence: 99%

See 1 more Smart Citation

Re: NSAID Use and Pancreatic Cancer Risk

Risch

2018

Gastroenterology

Self Cite

View full text Add to dashboard Cite

Section: Dear Editorsmentioning

confidence: 99%

Section: Dear Editorsmentioning

confidence: 99%

Re: NSAID Use and Pancreatic Cancer Risk

Risch

2018

Gastroenterology

Self Cite

View full text Add to dashboard Cite

Reply

et al. 2018

View full text Add to dashboard Cite

Can aspirin use reduce the risk of pancreatic cancer: an updated systematic review and meta-analysis

Zhou

Yang

et al. 2020

Journal of Pancreatology

View full text Add to dashboard Cite

Background: Chemoprevention effect of aspirin for pancreatic cancer (PC) remains unclear. Here we performed an updated systematic review and meta-analysis to investigate the real association between aspirin consumption and risk of PC. Methods: PubMed, Web of Science, EMBASE and the Cochrane Database were systematic searched to identify the potential studies. Odds ratio (ORs) with 95% confidence intervals (CIs) were applied to assess the strength of associations. Results: Thirteen studies and approximately 28,440 participants were included. Aspirin significantly reduced the incidence of PC (OR, 0.82; 95% CI, 0.73–0.93) in case-control studies. However, the overall results did not reveal an obvious association (OR, 0.92; 95% CI, 0.74–1.16). Both low-dose (OR = 0.86) and high-dose (OR = 0.80) aspirin intake showed prevention effect. In addition, low frequency (OR, 0.87; 95% CI, 0.73–1.05) and high frequency (OR, 0.84; 95% CI, 0.69–1.03) seemed to be equally associated with decreased risk for PC. Aspirin consumption longer than 10 years use seems to have better effect (OR, 0.73; 95% CI, 0.51–1.04) than shorter aspirin use (OR, 0.94; 95% CI, 0.77–1.15). Conclusions: Our study indicated that aspirin use might be associated with decreased risk of PC, especially at high doses. But we still need to be cautious when interpreting the results.

show abstract

Low-Dose Aspirin and Pancreatic Cancer Risk—Reply

Cited by 3 publications

References 5 publications

Re: NSAID Use and Pancreatic Cancer Risk

Re: NSAID Use and Pancreatic Cancer Risk

Reply

Can aspirin use reduce the risk of pancreatic cancer: an updated systematic review and meta-analysis

Contact Info

Product

Resources

About